Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRM421 in Dry Eye Syndrome
NCT04343287Phase 3Completed
- Sponsor
- BRIM Biotechnology, Inc.
- Start
- Jan 2020
- Primary completion
- Jun 2020
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of BRM421 in dry eye syndrome (DED), sponsored by BRIM Biotechnology, Inc.. Started Jan 2020; status: completed.
02
Drugs
BRM421
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04343287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04343287.